MAB885
抗乳头瘤病毒抗体，16L1，晚期蛋白，克隆号Cam Vir-1
clone Cam Vir-1, Chemicon®, from mouse
别名:
HPV
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
Cam Vir-1, monoclonal
Species reactivity:
human
Application:
IHC, IP, WB
Technique(s):
immunohistochemistry: suitable (paraffin), immunoprecipitation (IP): suitable, western blot: suitable
Citations:
10
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
Cam Vir-1, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin), immunoprecipitation (IP): suitable, western blot: suitable
isotype
IgG2a
shipped in
wet ice
Quality Level
Application
免疫沉淀、蛋白印迹和免疫荧光。
免疫组化。
在固定组织上显示反应性。 用pH 7.5-8.0的缓冲液稀释至所需工作体积。 对于广泛稀释，应使用含蛋白质或其他稳定介质。 最终工作稀释度必须由最终使用者进行确定。
免疫组化。
在固定组织上显示反应性。 用pH 7.5-8.0的缓冲液稀释至所需工作体积。 对于广泛稀释，应使用含蛋白质或其他稳定介质。 最终工作稀释度必须由最终使用者进行确定。
抗黏着斑蛋白抗体，16L1，晚期蛋白，克隆号Cam Vir-1，可检测黏着斑蛋白的水平，已发布，经验证可用于IP、WB、IH（P）。
研究子类别
传染病 - 病毒
传染病 - 病毒
研究类别
传染病
传染病
Biochem/physiol Actions
人类乳头瘤病毒16型的L1（晚期）蛋白。可用于研究宫颈涂片和活组织切片中的HPV。通过免疫沉淀、蛋白印迹、丙酮或多聚甲醛固定细胞的免疫荧光以及石蜡切片的免疫过氧化物酶染色，可识别HPV-16 L1。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Immunogen
含L1序列c端60%的β-半乳糖苷酶-HPV L1融合蛋白。
表位：16L1，晚期蛋白
Other Notes
浓度：请参考批次特异性浓缩物的检验报告。
Physical form
形式：纯化
溶液形式，溶于磷酸盐缓冲液（PBS），pH 7.4，含0.1％叠氮化钠。
Preparation Note
在-20°C下可保存长达12个月。 应避免反复冻/融循环。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Xue Chen et al.
Human vaccines & immunotherapeutics, 14(8), 2025-2033 (2018-04-24)
Current available human papillomavirus (HPV) vaccines are based on the major capsid protein L1 virus-like particles (VLPs), which mainly induce type-specific neutralizing antibodies against vaccine types. Continuing to add more types of VLPs in a vaccine raises the complexity and
Seroprevalence of seven high-risk HPV types in The Netherlands.
Mirte Scherpenisse,Madelief Mollers,Rutger M Schepp,Hein J Boot,Hester E de Melker et al.
Vaccine null
Valeria Russo et al.
Pathogens (Basel, Switzerland), 9(4) (2020-04-09)
Multiple papillomatous nodules were observed scattered over the amniotic membrane in six water buffaloes that had recently aborted. Grossly, some of the nodules had multiple villous projections while others appeared as single prominent conical or cylindrical horns. Histology revealed folded
Xue Chen et al.
Oncotarget, 8(38), 63333-63344 (2017-10-04)
The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. To this end, we constructed HPV16L1-58L2 chimeric
Mingrao Ma et al.
Frontiers in bioengineering and biotechnology, 10, 1073892-1073892 (2023-01-24)
Human papillomavirus (HPV) major capsid protein L1 virus-like particles (VLPs) produced in the baculovirus system showed excellent safety and immunogenicity, but the relatively high production cost stands as a substantial barrier to extensive commercialization, especially in producing multivalent vaccines. Here
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持